

HOLD

TP: Rs 153 | ▼ 5%

GAIL

| Oil & Gas

| 02 February 2026

Operational performance below expectations

- Revenue declined by 4.5%YoY and EBITDA by 7.6%YoY, impacted by Gas-transmission and Petchem performances
- Gas transmission volumes fell 4.6%YoY on the low offtake by Refinery and Fertiliser. Petchem reported higher loss YoY
- Based on 9M performance, revise rating to HOLD from SELL and TP to Rs153 from Rs158; based on EV/EBITDA of 5.5-6.5x Dec'27 EBITDA

Sukhwinder Singh
 Research Analyst
 research@bobcaps.in

Operational performance below expectations: Revenue was Rs352bn (-4.5% YoY, -1.0%QoQ) 4% above our estimates. EBITDA at Rs29bn (-7.6%YoY, -15.4% QoQ), was 11% below our estimates, due to lower than expected petchem performance which reported higher losses.

Gas transmission performance: Volume performance showed a 4.6% decline to 125mmscmd in Q3FY26 from 131mmscmd in Q3FY25. The YoY decline is due to the delay in pipeline connectivity, low offtake by refineries, power and fertiliser sectors. Volumes have recovered QoQ from 123mmscmd in Q2FY26. Management remains positive on the improvement in offtake and has guided for volumes of 124-125mmscmd for FY26E and 134-135mmscmd for FY27E.

Petchem continues to incur losses: Volumes fell 3.5%YoY to 218TMT v/s 226TMT in Q3FY25. Petchem business increased EBIT loss to Rs4,930mn from an EBIT loss of Rs33mn in Q3FY25. Prices of polypropylene end products continue to be weak, which impacted profitability.

Outlook on volumes: Management is positive on the gas consumption demand, owing to a likely uptick from refineries, power and fertiliser sectors. Volume growth is likely to be 8-9% for FY27E.

Capex: GAIL incurred a capex of Rs21bn in Q3FY26 and guided a capex of Rs107bn for FY26E.

Revise rating to HOLD and TP: Petchem business is likely to stay weak in the near term. Based on the 9M performance and stock correction, we revise the rating to HOLD from SELL and TP to Rs153 from Rs158; based on SoTP-based EV/EBITDA of 5.5-6.5x for the business segments on Dec'27 EBITDA.

Key changes

	Target	Rating
	▼	▲

Ticker/Price	GAIL IN/Rs 160
Market cap	US\$ 11.5bn
Free float	48%
3M ADV	US\$ 18.0mn
52wk high/low	Rs 203/Rs 151
Promoter/FPI/DII	52%/15%/19%


Source: NSE | Price as of 2 Feb 2026

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	1,419,035	1,432,678	1,566,055
EBITDA (Rs mn)	154,318	135,090	165,280
Adj. net profit (Rs mn)	124,498	86,904	105,775
Adj. EPS (Rs)	18.9	13.2	16.1
Consensus EPS (Rs)	18.9	12.6	15.1
Adj. ROAE (%)	15.4	10.0	11.6
Adj. P/E (x)	8.5	12.1	10.0
EV/EBITDA (x)	7.8	8.8	7.2
Adj. EPS growth (%)	76.3	25.8	(30.2)

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



Fig 1 – Quarterly performance

Rs mn	Q3FY26	Q2FY26	QoQ (%)	Q3FY25	YoY (%)	9MFY26	9MFY25	YoY (%)
Revenue	351,734	355,371	(1.0)	368,348	(4.5)	1,060,212	1,054,615	0.5
EBITDA	29,270	34,603	(15.4)	31,693	(7.6)	100,561	118,965	(15.5)
EBITDA margin (%)	8.32	9.74		8.60		9.48	11.28	
Depreciation	11,919	11,769	1.3	9,394	26.9	33,615	30,135	11.5
Interest	2,538	2,337	8.6	1,693	49.9	7,004	5,662	23.7
Other income	3,381	2,365	42.9	3,781	(10.6)	7,187	8,753	(17.9)
PBT	18,194	22,863	(20.4)	24,387	(25.4)	67,129	85,444	(21.4)
Tax	4,355	5,767	(24.5)	11,878	(63.3)	16,588	28,983	(42.8)
Reported PAT	17,291	19,887	(13.1)	40,843	(57.7)	61,001	93,096	(34.5)
Exceptional item	0	0	NA	24,400	(100.0)	0	24,400	(100.0)
Adjusted PAT	17,291	19,887	(13.1)	16,442	5.2	61,001	68,696	(11.2)
Adj. PATM (%)	4.92	5.60		11.09		5.75	6.51	
EPS (Rs)	2.63	3.02	(13.1)	2.50	5.2	9.28	10.45	(11.2)

Source: Company

Fig 2 – Q3FY26 Actual v/s Estimates


Particulars	Q3Actual	Estimates	VAR (%)
Revenue (Rs mn)	351,734	339,091	3.7
EBITDA (Rs mn)	29,270	32,755	(10.6)
EBITDA margin (%)	8.3	9.7	
PAT (Rs mn)	17,291	17,186	0.6
EPS (Rs)	2.6	2.6	0.61

Source: Company, Bloomberg


Fig 3 – Business performance

Particulars	Q3FY26	Q2FY26	QoQ (%)	Q3FY25	YoY (%)	9MFY26	9MFY25	YoY (%)
Natural gas transmission(mmscmd)	125.0	123.0	1.6	131.0	(4.6)	123.0	131.3	(6.3)
LPG transmission (Kt)	1,188.0	1,167.0	1.8	1,124.0	5.7	3,486.0	3,313.0	5.2
Natural gas marketing (mmscmd)	105.0	105.0	0.0	103.5	1.5	105.0	99.8	5.2
Polymer sales (Kt)	218.0	209.0	4.3	226.0	(3.5)	604.0	621.0	(2.7)


Source: Company

Fig 4 – Natural gas transmission


Source: Company

Fig 5 – LPG transmission

Source: Company

Fig 6 – Natural gas marketing

Source: Company

Fig 7 – Polymer sales

Source: Company

Call Highlights

- **Gas transmission business:** Volumes were subdued at 125mmscmd in Q3FY26 vs 131mmscmd in Q3FY25, due to the delay in pipeline connectivity, and low offtake from power and fertiliser sectors. Some of the power and fertiliser consumers shifted to alternate fuels on better price dynamics. Offtake has improved QoQ from 123mmscmd in Q2FY26. Utilisation was 56%. Volumes were 129mmscmd in Dec'25 indicating recovery in volumes. Recovery is on account of elevated consumption by fertiliser, refinery, CGD sectors and resumption of gas supply on two pipeline sections, following the completion of repair work. Going forward, management is positive about demand improvement and expects volumes of 124-125mmscmd for FY26E; and a further increase of 10mmscmd to 134-135mmscmd for FY27E.
- **Gas marketing business:** PBT was Rs29,420mn for 9MFY26. For FY26E, management guided for a PBT of Rs40,000mn.
- **Petchem business:** Reported EBIT loss due to increased gas input cost. Gas cost in Q3 was USD11.2/mmbtu vs USD9.5/mmbtu in Q3FY25. Polymer prices have risen by Rs3,000 per tonne since Dec'25. Gas costs have also gone up. Management expects performance to be at a similar level in the near term. Management is looking at cost optimisation measures to make it profitable. 60KTPA polypropylene plant at Pata is likely to be commissioned in 1-2 weeks.
- **Capex:** GAIL incurred a capex of Rs21,860mn in Q3FY26, which includes Rs8,040mn on the pipelines business, Rs4,550mn as operational capex and balance on CGD/other businesses.
- **Pipeline projects:** Ongoing projects 1) Mumbai-Nagpur-Jharsuguda pipeline (likely completion in FY27 2) Gurdaspur-Jammu pipeline (will likely be commissioned in FY27E).
- **GAIL gas business:** GAIL gas has 6 GA under the CGD business. It has 215 CNG stations and 4.6lakh DPNG connections. It added 2 CNG stations in Q3FY26. Volume is 0.55mmscmd. GAIL targets to add 85 new CNG stations in the next 2 years. It reported revenue of Rs33bn and PAT of Rs1bn in Q3FY26.

Valuation Methodology

Environment has been challenging in terms of gas transmission volume performance and petchem business.

Key changes in assumptions:

- We estimate decline in transmission gas volumes to be -2.6% vs the earlier -3.4%YoY in FY26E, 9.0% vs the earlier 6.5% in FY27E and 3.0% growth vs the earlier 5.3% In FY28E. Volumes estimated at 124mmscmd for FY26E, 135mmscmd for FY27E and 139mmscmd for FY28E.
- USD-INR assumption revised to Rs90.0 vs the earlier Rs88.5 for FY26E, Rs91.0 vs the earlier Rs89.5 for FY27E and Rs91.0 vs the earlier Rs89.5 for FY28E.

Fig 8 – Revision in Estimates

(Rs mn)	Actual	New			Old			Change (%)		
	FY25A	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	1,419,035	1,432,678	1,566,055	1,629,146	1,483,752	1,629,182	1,698,122	(3.4)	(3.9)	(4.1)
EBITDA	154,318	135,090	165,280	180,531	143,260	171,760	189,333	(5.7)	(3.8)	(4.6)
EBITDA % margin	10.9	9.4	10.6	11.1	9.7	10.5	11.1	-	-	-
PAT	124,498	86,904	105,775	115,332	97,413	113,488	118,711	(10.8)	(6.8)	(2.8)
EPS (Rs)	18.9	13.2	16.1	17.5	14.8	17.3	18.1	(10.8)	(6.8)	(2.8)

Source: Company

Fig 9 – Key assumptions

	FY24	FY25	FY26E	FY27E	FY28E
Transmission and Trading					
Transmission volumes (mmscmd)	120.0	127.3	124.0	135.0	139.0
Transmission tariff (Rs/scm)	2.3	2.3	2.4	2.6	2.6
% growth	3,678.8	0.0	298.2	885.3	0.0
Rs/mmbtu	58.6	58.6	60.3	65.7	65.7
Gas Trading					
Blended realization (USD/mmbtu)	14.0	12.0	11.5	11.6	11.6
Margin (Rs/000scm)	850	800	900	910	915
Petrochemicals					
Utilization (%)	85.0	90.0	90.0	90.0	90.0
Volumes (mn MT)	0.7	0.8	0.8	0.9	0.9
HDPE price (USD/MT)	1,200	1,200	1,080	1,225	1,225
Spot LNG price (USD/mmbtu)	12.5	12.5	12.5	12.8	12.8
LPG/OLHC					
LPG price (USD/MT)	710	710	710	710	725
Gas cost (USD/mmbtu)	7.5	7.5	7.5	7.5	7.5
USD-INR	82.8	87.0	89.0	91.0	91.0

Source: Company

EV/EBITDA-based Valuation Rationale

Based on 9M performance as also the recent stock correction, we revise our rating to HOLD from SELL and TP to Rs153 from Rs158; based on SoTP-based EV/EBITDA of 5.5-6.5x for the business segments on Dec'27 EBITDA.

- Multiple of 6.5x for Gas and LPG transmission businesses – in line with commodity cycle
- Multiple of 6.0x for Petchem business
- Multiple of 5.5x for LPG business

Fig 10 – Valuation summary



Business	Dec.27 EBITDA (Rs mn)	Multiple (x)	Holding co. discount (%)	Rs mn	Value (Rs/share)
Pipeline (Gas + LPG transmission)	92,499	6.5	NA	604,944	92
Natural Gas Trading	20,917	6.5	NA	135,961	21
Petchem	(1,197)	6.0	NA	(7,184)	(1)
LPG	70,036	5.5	NA	385,195	59
Sub-total	182,254			1,118,917	170
CGD investments	2xBV/25% Holding co discount		25	10,776	2
Investment in other PSUs	40% discount to CMP		40	7,407	1
Investment in Konkan LNG	1.5xBV, 20% discount		20	882	0
Other investments	BV/CMP at discount		25	682	0
Total EV				1,138,665	173
Less - Net Debt				135,869	21
Target price (Rs)				1,002,796	153

Source: Company, BOBCAPS Research

Key Risks

Key risks to our estimates:

- **Petchem business performance relies on prices of LNG and end products:** GAIL has been using imported LNG as a feedstock for Petchem plant. In FY23, the cost moved up due to the elevated LNG price. This has made EBITDA performance volatile since then. In the last 4 quarters, the business continues to report EBIT losses. We expect this risk to increase. GAIL is looking to use Ethane as a feedstock, where the price volatility is relatively less and thus, would bring in stability in the EBITDA of the business.
- **Offtake in Gas transmission business:** Volume offtake depends on favourable pricing vs alternate fuels. Therefore, if LNG pricing gets favourable, we may see a faster offtake from various sectors. This would ramp up GAIL's revenue and EBITDA growth.

Fig 11 – EV/EBITDA 1YF**Fig 12 – P/B 1YF**

Financials

Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Total revenue	1,332,285	1,419,035	1,432,678	1,566,055	1,629,146
EBITDA	142,963	154,318	135,090	165,280	180,531
Depreciation	(36,720)	(37,992)	(45,037)	(51,795)	(55,995)
EBIT	116,321	129,002	102,983	126,673	137,988
Net interest inc./exp.)	(7,192)	(7,480)	(7,338)	(6,219)	(5,181)
Other inc./exp.)	10,078	12,676	12,930	13,189	13,452
Exceptional items	0	0	0	0	0
EBT	109,129	145,923	95,645	120,454	132,807
Income taxes	(26,922)	(36,326)	(24,074)	(30,318)	(33,428)
Extraordinary items	0	24,400	0	0	0
Min. int./Inc. from assoc.	16,785	14,902	15,333	15,640	15,953
Reported net profit	98,992	124,498	86,904	105,775	115,332
Adjustments	0	0	0	0	0
Adjusted net profit	98,992	124,498	86,904	105,775	115,332

Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	66,397	77,599	79,326	87,783	92,436
Other current liabilities	81,228	76,337	76,337	76,337	76,337
Provisions	10,761	9,797	9,797	9,797	9,797
Debt funds	186,080	163,074	163,074	148,074	109,074
Other liabilities	130,749	152,277	152,277	152,277	152,277
Equity capital	65,751	65,751	65,751	65,751	65,751
Reserves & surplus	704,221	784,225	818,528	868,415	924,571
Shareholders' fund	769,972	849,976	884,279	934,166	990,322
Total liab. and equities	1,247,172	1,331,487	1,367,518	1,410,862	1,432,671
Cash and cash eq.	17,121	27,205	26,765	27,161	27,991
Accounts receivables	95,803	94,364	95,272	104,141	108,337
Inventories	59,700	62,499	63,100	68,974	71,753
Other current assets	29,368	30,204	30,204	30,204	30,204
Investments	219,100	227,646	227,646	227,646	227,646
Net fixed assets	479,567	493,529	528,492	556,696	570,701
CWIP	236,268	274,211	274,211	274,211	274,211
Intangible assets	72,318	94,826	94,826	94,826	94,826
Deferred tax assets, net	0	0	0	0	0
Other assets	84,348	181,889	218,942	225,700	239,900
Total assets	1,247,172	1,331,487	1,367,518	1,410,862	1,432,671

Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Cash flow from operations	148,516	159,733	124,166	141,864	158,234
Capital expenditures	(161,439)	(112,405)	(80,000)	(80,000)	(70,000)
Change in investments	(46,617)	(8,546)	0	0	0
Other investing cash flows	(371)	11,174	0	0	0
Cash flow from investing	(208,427)	(109,777)	(80,000)	(80,000)	(70,000)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	23,331	(23,006)	0	(15,000)	(39,000)
Interest expenses	(7,192)	(7,480)	(7,338)	(6,219)	(5,181)
Dividends paid	(33,095)	(49,313)	(52,601)	(55,888)	(59,176)
Other financing cash flows	65,084	82,958	39,927	15,333	15,640
Cash flow from financing	66,003	(39,872)	(44,606)	(61,468)	(87,404)
Chg in cash & cash eq.	6,092	10,084	(440)	396	830
Closing cash & cash eq.	17,121	27,205	26,765	27,161	27,991

Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	15.1	18.9	13.2	16.1	17.5
Adjusted EPS	15.1	18.9	13.2	16.1	17.5
Dividend per share	5.0	7.5	8.0	8.5	9.0
Book value per share	117.1	129.3	134.5	142.1	150.6

Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	0.9	0.9	0.8	0.8	0.7
EV/EBITDA	8.5	7.8	8.8	7.2	6.4
Adjusted P/E	10.7	8.5	12.1	10.0	9.1
P/BV	1.4	1.2	1.2	1.1	1.1

DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	75.3	75.1	74.8	74.8	74.8
Interest burden (PBT/EBIT)	0.9	0.9	0.9	1.0	1.0
EBIT margin (EBIT/Revenue)	8.7	9.1	7.2	8.1	8.5
Asset turnover (Rev./Avg TA)	1.1	1.1	1.1	1.1	1.1
Leverage (Avg TA/Avg Equity)	0.0	0.0	0.0	0.0	0.0
Adjusted ROAE	14.0	15.4	10.0	11.6	12.0

Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	40.8	(8.5)	6.5	1.0	9.3
EBITDA	(64.9)	91.0	7.9	(12.5)	22.3
Adjusted EPS	(72.0)	76.3	25.8	(30.2)	21.7
Profitability & Return ratios (%)					
EBITDA margin	10.7	10.9	9.4	10.6	11.1
EBIT margin	8.7	9.1	7.2	8.1	8.5
Adjusted profit margin	7.4	8.8	6.1	6.8	7.1
Adjusted ROAE	14.0	15.4	10.0	11.6	12.0
ROCE	11.5	11.4	8.7	10.4	11.1
Working capital days (days)					
Receivables	26	24	24	24	24
Inventory	16	16	16	16	16
Payables	20	22	22	23	23
Ratios (x)					
Gross asset turnover	1.1	1.1	1.1	1.1	1.1
Current ratio	0.9	1.0	1.0	1.0	1.0
Net interest coverage ratio	16.2	17.2	14.0	20.4	26.6
Adjusted debt/equity	0.2	0.2	0.2	0.1	0.1

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025

Brand Name: **BOBCAPS**

Trade Name: www.barodaetrade.com

CIN: U65999MH1996GOI098009

Logo:  TRUST | INNOVATION | EXCELLENCE

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): GAIL (GAIL IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.